What to Do When Your Manufacturing Team Can’t Keep Pace With Technical Demands
Manufacturing science and technology is one of the most technically demanding disciplines in pharmaceutical development. It sits at the intersection of chemistry, engineering, process design, regulatory science, and quality, and it evolves continuously as programmes progress from early development through to commercial scale. The demands it places on a manufacturing team are significant, and they intensify at precisely the moments when pressure is highest: at technology transfer, at scale-up, at process validation, and at the point of submission.
When a manufacturing team cannot keep pace with those demands, the consequences are rarely contained. Timelines slip. Data gaps emerge. Regulatory submissions are delayed or weakened. CMDOs lose confidence. And the scientific credibility of the programme, built over years of careful development work, is put at risk by technical gaps that could have been addressed earlier.
This article is for development leaders, CMC heads, and programme sponsors who recognise this pattern and want to understand what to do about it: how to diagnose where the gap is, how to address it without disrupting the programme, and how to build the technical capacity the programme needs to move forward.
1. Recognising the Gap Before It Becomes a Problem
The manufacturing capability gap rarely appears suddenly. It accumulates. A team that was well-matched to the demands of early development becomes progressively less well-matched as the programme scales and the technical requirements intensify. By the time the gap becomes visible as a missed milestone or a failed process validation, it has usually been present for months.
The early signals are worth knowing. They include:
• Technology transfer timelines that are consistently longer than planned, with explanations that focus on the CDMO rather than internal technical readiness.
• Process development data that is thinner than the stage of development warrants, with gaps in understanding of critical process parameters and their relationship to critical quality attributes.
• Increasing reliance on the CDMO to make technical decisions that should sit with the sponsor organisation.
• CMC sections of regulatory documents that are descriptive rather than mechanistic, reflecting an absence of genuine process understanding rather than a decision to present information at a high level.
• Scale-up failures or unexpected process deviations that the team struggles to explain with reference to first principles.
• A team that is fully occupied with day-to-day execution and has no capacity for the forward-looking technical work the programme needs.
None of these signals is catastrophic in isolation. Together, they indicate a manufacturing function that is at or beyond its technical capacity. The right response is to address the gap before it becomes visible to a regulator or a development partner.
The Critical Moment
The manufacturing capability gap is most damaging when it surfaces at a high-stakes moment: a regulatory submission, a pre-approval inspection, or a technology transfer to a new CDMO. Addressing it proactively, before those moments arrive, is significantly less costly than addressing it under pressure.
2. Understanding What Kind of Gap You Have
Not all manufacturing capability gaps are the same, and the right response depends on correctly diagnosing which type of gap you are dealing with. There are three distinct categories, and they often coexist.
Capacity gaps
A capacity gap exists when the team has the technical capability to address the demands of the programme but does not have enough time or resource to do so. The team is capable but stretched. The solution is additional resource, either through hiring or through bringing in external support to absorb the workload and free the existing team to focus on the highest-priority activities.
Expertise gaps
An expertise gap exists when the programme has moved into technical territory that the current team does not have deep experience in. This is common at the transition from early to late-phase development, when the demands shift from proof-of-concept process development to the kind of rigorous, mechanistic process understanding that a regulatory submission requires. It is also common when a programme involves a modality, a formulation type, or a manufacturing platform that is outside the core experience of the team.
Expertise gaps cannot be solved with additional resource alone. They require access to specialists who have done this specific type of work before and who can provide the technical depth the programme needs.
Structural gaps
A structural gap exists when the manufacturing function is not designed in a way that supports the demands of the programme. This might manifest as a lack of defined ownership for CMC strategy, an absence of a formal technology transfer process, or a team structure that does not have a clear interface between process development, analytical science, and manufacturing operations. Structural gaps require organisational and process design intervention, not just additional resource or expertise.
Not Sure What Kind of Gap You Have?
TDP provides rapid CMC and MS&T capability assessments for pharmaceutical development organisations. In a structured engagement, we identify the nature and extent of your manufacturing capability gap and provide a prioritised plan for addressing it.
3. The Options for Closing the Gap
Once the nature of the gap is understood, there are four broad approaches to closing it. The right choice depends on the type of gap, the stage of the programme, and the timeline pressure the organisation is under.
Bring in specialist external support
For expertise gaps and time-critical capacity gaps, the fastest and most targeted response is specialist external support. An experienced MS&T or CMC consultant embedded in the programme can address a specific technical challenge, provide the expertise the team lacks, and deliver tangible outputs, a process characterisation study, a technology transfer package, a regulatory submission section, within a defined timeframe.
This model works particularly well when the gap is in a specific area rather than a general capability deficit. A team that has deep small molecule experience but is navigating a biologics programme for the first time, or a process development group that needs senior regulatory CMC input on a submission strategy, can benefit from precisely targeted external expertise without restructuring the entire function.
Augment the team with embedded resource
For capacity gaps and longer-term expertise gaps, embedded resource provides more sustained support. An experienced MS&T professional working alongside the internal team over an extended period transfers knowledge and capability as well as delivering outputs. Over time, the internal team becomes more capable. The embedded model is particularly valuable for organisations that are scaling rapidly and need their team to grow in capability, not just in headcount.
Outsource defined workstreams
For discrete, well-defined pieces of work, full outsourcing to a specialist organisation is often the most efficient model. Technology transfer management, process validation protocol development, CMC dossier preparation, and comparability study design are all workstreams that can be scoped and delivered by an external team with the appropriate expertise, freeing the internal organisation to focus on the activities where its presence is most valuable.
Restructure and build internal capability
For structural gaps, and for organisations that recognise a longer-term mismatch between their technical ambitions and their current capability, a more fundamental response may be required. This might involve redesigning the manufacturing function, defining new roles, establishing new processes for technology transfer and CMC governance, and building the internal capability the programme will need at commercial scale. This is a longer-term investment that is best initiated early, before the gap becomes a programme constraint rather than a development priority.
On Timing
The cost of closing a manufacturing capability gap increases significantly the later it is addressed. External support engaged six months before a process validation campaign costs a fraction of the remediation required when a validation campaign fails for reasons that were predictable. The right time to address a capability gap is as soon as it is identified.
4. Managing the CDMO Relationship When Your Team Is Under-Resourced
One of the most common consequences of a manufacturing capability gap is that the CDMO relationship shifts out of balance. The sponsor organisation, unable to provide adequate technical oversight, becomes increasingly dependent on the CDMO to make decisions that should sit on the sponsor side. The CDMO, aware of this dynamic, may fill the vacuum or may simply proceed with its own preferred approaches without the scientific challenge that good sponsor oversight provides.
Neither outcome serves the programme well. A CDMO operating without adequate sponsor oversight is a regulatory risk. The sponsor remains accountable for the quality of the manufactured product regardless of who manufactures it. If a CMC submission contains process understanding that originates from the CDMO rather than the sponsor, and the sponsor cannot demonstrate genuine comprehension of that understanding, the submission is vulnerable.
Maintaining genuine technical oversight of a CDMO requires sponsor-side capability. When that capability is limited, external MS&T support can fulfil the technical sponsor role: attending manufacturing runs, reviewing batch records and deviation reports, challenging process development data, and ensuring that the scientific understanding generated at the CDMO is properly captured and owned by the sponsor organisation.
5. The Regulatory Dimension
Manufacturing capability gaps have a direct and well-documented impact on regulatory outcomes. The quality and depth of CMC sections in regulatory submissions is directly correlated with the sponsor’s genuine understanding of their manufacturing process. Submissions that describe what happens during manufacturing, without demonstrating mechanistic understanding of why it happens, are increasingly subject to regulatory queries and requests for additional information.
FDA and MHRA both expect sponsors to be able to demonstrate control of their manufacturing process, not merely to report that manufacturing has occurred successfully. Process characterisation data, the establishment of design space, the definition of critical process parameters and their proven acceptable ranges, and the linkage of process parameters to critical quality attributes: these are not regulatory formalities. They are the evidence base that demonstrates the sponsor understands and controls their process.
A manufacturing team that is at the limit of its technical capacity will typically produce CMC documentation that is thinner than it should be at the relevant development stage. The consequences surface at submission, when regulatory questions identify gaps that require additional studies, and at pre-approval inspection, when an inspector’s technical questions cannot be answered with the depth the agency expects.
External MS&T support engaged specifically to strengthen the CMC evidence base, and to ensure that the regulatory submission reflects genuine process understanding, is one of the highest-value interventions available to a development organisation facing this challenge.
TDP’s MS&T and CMC Consulting Services
TDP provides manufacturing science and technology support for pharmaceutical development organisations at every stage of the development journey. From process characterisation and technology transfer through CMC regulatory strategy and submission support, our MS&T consultants bring the technical depth and regulatory fluency your programme needs. We work alongside your existing team or take full ownership of defined workstreams, depending on what your programme requires.
6. Building for the Future: Getting Ahead of the Demand Curve
The most effective approach to manufacturing capability gaps is to anticipate them rather than respond to them. The technical demands on a manufacturing team are broadly predictable from the programme timeline. Technology transfer, process characterisation, scale-up, process validation, and submission preparation each place known demands on the team at known points in the development journey. Planning the team’s capability against those demands, and identifying where gaps will arise before they arrive, is a straightforward exercise that is rarely done with sufficient rigour.
A CMC capability review conducted 12 to 18 months before a major technical milestone provides the lead time to address gaps properly. Whether the response is external support, embedded resource, structural change, or a combination, having sufficient time to implement it without programme disruption is a significant advantage. The organisations that manage manufacturing capability well are those that treat it as a forward-looking planning exercise, not a reactive crisis management challenge.
Final Thought
A manufacturing team that cannot keep pace with the technical demands of a programme is not a failing. It is a mismatch between capability and requirement that is extremely common in pharmaceutical development, particularly as programmes scale and the demands intensify. What matters is identifying the mismatch early, understanding its nature accurately, and responding with the right combination of external expertise, additional resource, and structural improvement.
The programmes that suffer most from manufacturing capability gaps are not those where the gap is largest. They are those where it is recognised latest. The gap that is identified and addressed twelve months before a process validation campaign is a manageable development challenge. The same gap identified during a pre-approval inspection is a different problem entirely.
If the signals described in this article are recognisable in your programme, the time to act is now.
Talk to TDP About Your Manufacturing Capability
TDP’s MS&T and CMC consulting team works with pharmaceutical and biotech organisations to identify and close manufacturing capability gaps before they become programme constraints. Get in touch for a confidential conversation with one of our senior consultants.